Literature DB >> 21947984

The diagnostic and prognostic value of first hour glycogen phosphorylase isoenzyme BB level in acute coronary syndrome.

Sebnem Bozkurt1, Ergun Baris Kaya, Sercan Okutucu, Kudret Aytemir, Figen Coskun, Ali Oto.   

Abstract

BACKGROUND: Evaluating patients with symptoms suggestive of acute coronary syndrome (ACS) is a time consuming, expensive and problematic process in the emergency department. This study aimed to evaluate the diagnostic and prognostic value of glycogen phosphorylase isoenzyme-BB (GP-BB) in ACS.
METHODS: A total of 72 patients (mean age 61.8 ± 11.6 years) with ACS were enrolled. The ELISA method for determining GP-BB level was performed and considered positive at 〉 10 ng/mL. Duration of angina, type of ACS, demographic features, myoglobin, creatinine kinase and troponin T (cTnT) were also assessed. The cTnT levels eight hours after pain onset was considered the gold standard test for the diagnosis of myocardial infarction.
RESULTS: The most sensitive biomarker at first hour of admission was GP-BB (95.8%). However, the specificity of GP-BB was low (43.7%). Receiver operating characteristics curve analysis of the GP-BB level for predicting myocardial infarction revealed the area under the curve value as 0.82 (SE 0.04; 95% CI 0.78-0.85). Positive treadmill exercise test (60% vs 17%, p = 0.047), coronary artery disease (CAD; 59% vs 19%, p = 0.007), percutaneous coronary intervention (44% vs 27%, p = 0.031) and 30-day mortality and/or readmission (33% vs 5%, p = 0.028) were found to be higher in unstable angina (UA) patients having GP-BB (+).
CONCLUSIONS: GP-BB is considerably cardiosensitive at the first hour of admission in patients with ACS, but the specificity of GP-BB is lower and it is elevated in nearly half of the patients with UA. However, in this group, GP-BB predicts significant CAD and the combined end-point of mortality and re-hospitalization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947984     DOI: 10.5603/cj.2011.0004

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  7 in total

1.  Glycogen Phosphorylase BB: A more Sensitive and Specific Marker than Other Cardiac Markers for Early Diagnosis of Acute Myocardial Infarction.

Authors:  Neelima Singh; Vedika Rathore; Roshan Kumar Mahat; Puneet Rastogi
Journal:  Indian J Clin Biochem       Date:  2017-08-03

Review 2.  Blood Biomarkers for Stroke Diagnosis and Management.

Authors:  Joseph Kamtchum-Tatuene; Glen C Jickling
Journal:  Neuromolecular Med       Date:  2019-03-04       Impact factor: 3.843

3.  Glycogen Phosphorylase Isoenzyme Bb, Myoglobin and BNP in ANT-Induced Cardiotoxicity.

Authors:  Jia-Yin Di; Zong-Xin Zhang; Shao-Jun Xin
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

4.  Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management.

Authors:  Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier
Journal:  Biomark Insights       Date:  2013-09-03

5.  Glycogen phosphorylase isoenzyme BB in the diagnosis of acute myocardial infarction: a meta-analysis.

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Ivan Comelli; Gianfranco Cervellin
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

6.  Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome.

Authors:  Zlatko Cubranic; Zeljko Madzar; Sanja Matijevic; Stefica Dvornik; Elizabeta Fisic; Vjekoslav Tomulic; Juraj Kunisek; Gordana Laskarin; Igor Kardum; Luka Zaputovic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

Review 7.  Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients.

Authors:  Lukasz Szarpak; Marcin Lapinski; Aleksandra Gasecka; Michal Pruc; Wiktoria L Drela; Mariusz Koda; Andrea Denegri; Frank W Peacock; Miłosz J Jaguszewski; Krzysztof J Filipiak
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.